You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
This volume is the first text to concisely yet comprehensively cover developments for both alcoholic and nonalcoholic fatty liver disease in an organized fashion. Aspects of these two diseases covered in the book include global epidemiology and risk factors, pathogenesis, animal models, hepatic and extra-hepatic malignancies, treatment models, and current and emerging therapies. Written by experts in the field, Alcoholic and Non-Alcoholic Fatty Liver Disease: Bench to Bedside is a valuable resource for gastroenterologists, pathologists, and hepatologists who treat patients with alcoholic and nonalcoholic fatty liver disease.
Practical Hepatic Pathology—a new volume in the new Pattern Recognition series—offers you a practical guide to diagnosing every challenging liver biopsy that you encounter in your daily practice. Dr. Romil Saxena presents diagnoses according to a pattern-based organization that guides you from a histological pattern of injury, through the appropriate work-up, around the pitfalls, and to the best diagnosis. Lavish, full-color images capture key hepatic pathology patterns of injury, pathognomonic features and common variations of all major liver diseases and hepatic neoplasms. No other single source delivers the practical, hands-on information you need to solve even the toughest diagnostic...
For more than 95 years, Goldman-Cecil Medicine has been the authoritative source for internal medicine and the care of adult patients. Every chapter is written by acclaimed experts who, with the oversight of our editors, provide definitive, unbiased advice on the diagnosis and treatment of thousands of common and uncommon conditions, always guided by an understanding of the epidemiology and pathobiology, as well as the latest medical literature. But Goldman-Cecil Medicine is not just a textbook. It is designed to optimize electronic searches that will rapidly take you to exactly the information you are seeking. Throughout the lifetime of each edition, periodic updates continually include the...
In this issue of Clinics in Liver Disease, guest editor Dr. Nikolaos T. Pyrsopoulos brings his considerable expertise to the topic of Acute-on-Chronic Liver Failure. Recent studies indicate that as many as one in four patients with cirrhosis develop acute-on-chronic liver failure (ACLF) and 25% die within one month. This issue, the first devoted to this topic, provides thorough coverage of critical clinical interventions, including diagnosis, treatment, and management. It also focuses on early recognition of ACLF, which is important for the initiation of aggressive management and ultimately, saving lives. - Contains 17 practice-oriented topics including ACLF: mechanisms of disease and multis...
This book discusses clinical advances in hepatology, with a focus on metabolic diseases and chronic hepatitis C. The development of direct-acting antiviral (DAA) agents for the treatment of hepatitis C virus (HCV) infection in 2010 has completely transformed the management of this disease. This transformative nature of DAA therapy underpins the goal of the World Health Organization (WHO) to eliminate HCV infection as a public health threat by 2030. The advantages of using these therapies include high efficacy (sustained virological response rate >95%) with minimal side effects, good tolerability, easy drug administration (once-daily oral dosing) and short duration of treatment (8-12 weeks). The commercialization of second-generation DAA agents due to their high effectiveness, few side-effects and pangenotypic action. This transformative nature of DAA therapy underpins the goal of the WHO to eliminate HCV infection as a public health threat by 2030.
This field has shown tremendous growth in recent years, primarily due to the recognition that drug-induced liver disease is the most common cause of liver failure and one of the major contributors to the withdrawal of drugs developed by the pharmaceutical industry. Drug-Induced Liver Disease, 3rd edition is a comprehensive reference that covers mechanisms of injury, diagnosis and management, major hepatotoxins, regulatory perspectives and much more. Written by highly respected authorities, this new edition is an updated and definitive reference for clinicians and scientists in academia, the pharmaceutical industry and government settings. This book contains 4 new chapters on key topics in th...
Obesity has devastating effects on a patient's overall health, with specific negative effects on organ systems, long-term. The hepatologist must often manage diseases of the liver and pancreas as a result of obesity. This issue will provide a current update on the diagnosis, treatment, and management of NAFLD and NASH. Dr. Bernstein has assembled the top leaders in the field to provide timely clinical reviews. Articles are devoted to the following topics: Clinical and economic burden of NAFLD/NASH; NAFLD/NASH in children and its implications; Natural history of NAFLD/NASH; Diagnosis and evaluation of NAFLD/NASH; Radiological imaging in NAFLD/NASH; The use of liver biopsy in NAFLD: When to biopsy and in whom; Pathophysiology of NAFLD/NASH; Risk factors for the development of NAFLD/NASH including genetics; Role of intestinal microbes in NAFLD/NASH; NAFLD/NASH and the metabolic syndrome; NAFLD/NASH and lipid and insulin resistance; NAFLD/NASH and cardiac disease; Current treatment of NAFLD/NASH; Emerging treatment of NAFLD/NASH; NAFLD/NASH and HCC and NAFLD/NASH and liver transplantation. Readers will have a clear understanding of how to manage outcomes for these patients.
Packed with Board-focused hints, case studies and an online Board-standard MCQ test offering CME credits, this fantastic book covers every gastroenterology disease and symptom you’re likely to encounter and is the perfect tool to prepare for Board exams and certification.